一项新的研究发现,在12个月内复发(TTR12)有力地预测,激进的T细胞淋巴瘤的存活率很低,有助于医生更早地发现高风险病人。 A new study finds relapse within 12 months (TTR12) strongly predicts poor survival in aggressive T-cell lymphoma, helping doctors identify high-risk patients earlier.

由麻省麻省理工学院和麻省综合医院牵头的一项新研究确定,TTR12在治疗后12个月内复发,是侵略性节点成熟T细胞淋巴瘤(一种罕见和致命的血癌)中生存不良的有力预测者。 A new study led by MIT and Massachusetts General Hospital identifies TTR12—relapse within 12 months of treatment—as a powerful predictor of poor survival in aggressive nodal mature T-cell lymphoma, a rare and deadly blood cancer. 研究人员采用称为合成生存控制(合成生存控制)的因果推断方法,发现标记预测结果,而不论治疗类型或现有风险分数如何。 Using a causal inference method called Synthetic Survival Controls, researchers found the marker predicts outcomes regardless of treatment type or existing risk scores. 该工具使“何时-如果”分析能够估计不同疗法下生存可能发生何种变化,帮助临床医生更早地识别高风险病人,并更快地考虑有针对性的治疗或临床试验。 The tool enables "when-if" analyses to estimate how survival might change under different therapies, helping clinicians identify high-risk patients earlier and consider targeted treatments or clinical trials sooner. 该方法由麻省理工学院研究生Jessy Han制定,可以改善个性化护理,并适用于肿瘤学以外。 The approach, developed by MIT graduate student Jessy Han, could improve personalized care and is applicable beyond oncology. 调查结果在《Blood》中发表。 Findings were published in Blood.